000287682 001__ 287682
000287682 005__ 20250318132935.0
000287682 0247_ $$2doi$$a10.1213/ANE.0000000000006812
000287682 0247_ $$2pmid$$apmid:38335141
000287682 0247_ $$2ISSN$$a0003-2999
000287682 0247_ $$2ISSN$$a1526-7598
000287682 037__ $$aDKFZ-2024-00310
000287682 041__ $$aEnglish
000287682 082__ $$a610
000287682 1001_ $$aKlotz, Rosa$$b0
000287682 245__ $$aThoracic Epidural Analgesia Is Not Associated With Improved Survival After Pancreatic Surgery: Long-Term Follow-Up of the Randomized Controlled PAKMAN Trial.
000287682 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2025
000287682 3367_ $$2DRIVER$$aarticle
000287682 3367_ $$2DataCite$$aOutput Types/Journal article
000287682 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742300917_23104
000287682 3367_ $$2BibTeX$$aARTICLE
000287682 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287682 3367_ $$00$$2EndNote$$aJournal Article
000287682 500__ $$a 140(4):p 798-810, April 2025.
000287682 520__ $$aPerioperative thoracic epidural analgesia (EDA) and patient-controlled intravenous analgesia (PCIA) are common forms of analgesia after pancreatic surgery. Current guidelines recommend EDA over PCIA, and evidence suggests that EDA may improve long-term survival after surgery, especially in cancer patients. The aim of this study was to determine whether perioperative EDA is associated with an improved patient prognosis compared to PCIA in pancreatic surgery.The PAKMAN trial was an adaptive, pragmatic, international, multicenter, randomized controlled superiority trial conducted from June 2015 to October 2017. Three to five years after index surgery a long-term follow-up was performed from October 2020 to April 2021.For long-term follow-up of survival, 109 patients with EDA were compared to 111 patients with PCIA after partial pancreatoduodenectomy (PD). Long-term follow-up of quality of life (QoL) and pain assessment was available for 40 patients with EDA and 45 patients with PCIA (questionnaire response rate: 94%). Survival analysis revealed that EDA, when compared to PCIA, was not associated with improved overall survival (OS, HR, 1.176, 95% HR-CI, 0.809-1.710, P = .397, n = 220). Likewise, recurrence-free survival did not differ between groups (HR, 1.116, 95% HR-CI, 0.817-1.664, P = .397, n = 220). OS subgroup analysis including only patients with malignancies showed no significant difference between EDA and PCIA (HR, 1.369, 95% HR-CI, 0.932-2.011, P = .109, n = 179). Similar long-term effects on QoL and pain severity were observed in both groups (EDA: n = 40, PCIA: n = 45).Results from this long-term follow-up of the PAKMAN randomized controlled trial do not support favoring EDA over PCIA in pancreatic surgery. Until further evidence is available, EDA and PCIA should be considered similar regarding long-term survival.
000287682 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000287682 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287682 7001_ $$0P:(DE-He78)bac8c2c56238485ecf0475ff14438430$$aAhmed, Azaz$$b1$$udkfz
000287682 7001_ $$aTremmel, Anja$$b2
000287682 7001_ $$aBüsch, Christopher$$b3
000287682 7001_ $$aTenckhoff, Solveig$$b4
000287682 7001_ $$aDoerr-Harim, Colette$$b5
000287682 7001_ $$aLock, Johan F$$b6
000287682 7001_ $$aBrede, Elmar-Marc$$b7
000287682 7001_ $$aKöninger, Jörg$$b8
000287682 7001_ $$aSchiff, Jan-Henrik$$b9
000287682 7001_ $$aWittel, Uwe A$$b10
000287682 7001_ $$aHötzel, Alexander$$b11
000287682 7001_ $$aKeck, Tobias$$b12
000287682 7001_ $$aNau, Carla$$b13
000287682 7001_ $$aAmati, Anca-Laura$$b14
000287682 7001_ $$aKoch, Christian$$b15
000287682 7001_ $$aDiener, Markus K$$b16
000287682 7001_ $$aWeigand, Markus A$$b17
000287682 7001_ $$aBüchler, Markus W$$b18
000287682 7001_ $$aKnebel, Phillip$$b19
000287682 7001_ $$aLarmann, Jan$$b20
000287682 773__ $$0PERI:(DE-600)2018275-2$$a10.1213/ANE.0000000000006812$$n4$$p798-810$$tAnesthesia & analgesia$$v140$$x0003-2999$$y2025
000287682 909CO $$ooai:inrepo02.dkfz.de:287682$$pVDB
000287682 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bac8c2c56238485ecf0475ff14438430$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000287682 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000287682 9141_ $$y2024
000287682 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-22$$wger
000287682 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANESTH ANALG : 2022$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000287682 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANESTH ANALG : 2022$$d2023-10-22
000287682 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000287682 980__ $$ajournal
000287682 980__ $$aVDB
000287682 980__ $$aI:(DE-He78)D196-20160331
000287682 980__ $$aUNRESTRICTED